General form of registration statement for all companies including face-amount certificate companies

Commitments and Contingencies (Details)

v3.24.0.1
Commitments and Contingencies (Details)
£ in Millions
 1 Months Ended 6 Months Ended 12 Months Ended
Dec. 20, 2022
item
Aug. 18, 2021
lawsuit
Jun. 25, 2021
lawsuit
Jun. 04, 2021
lawsuit
Dec. 31, 2019
USD ($)
D
Nov. 30, 2023
USD ($)
May 31, 2023
USD ($)
item
May 31, 2023
GBP (£)
Jan. 31, 2022
USD ($)
Jan. 06, 2022
USD ($)
Dec. 31, 2021
USD ($)
Shareholder Derivative Lawsuits                      
Commitments and Contingencies                      
Number of additional shareholder derivative lawsuits | lawsuit   2 2                
Consolidated number of lawsuits | lawsuit       3              
Securities and Exchange Commission and Department of Justice Investigations | Mr. Pourhassan                      
Commitments and Contingencies                      
Number of conspiracy charges | item 1                    
Number of security fraud charges | item 4                    
Number of wire fraud charges | item 3                    
Number of insider trading charges | item 3                    
Securities and Exchange Commission and Department of Justice Investigations | Kazem Kazempour                      
Commitments and Contingencies                      
Number of conspiracy charges | item 1                    
Number of security fraud charges | item 3                    
Number of wire fraud charges | item 2                    
Number of insider trading charges | item 1                    
Samsung BioLogics Co., Ltd. ("Samsung")                      
Commitments and Contingencies                      
Forecast period           3 years 3 years        
Amount of material breach of' Master Services and Project Specific Agreements | $                   $ 13,500,000 $ 13,500,000
Additional Contractual Obligation | $                 $ 22,800,000    
Past due balance | $           $ 232,788,000 $ 232,788,000        
License Agreements With Vyera Pharmaceuticals, LLC                      
Commitments and Contingencies                      
Amount payable upon achievement of sales and regulatory milestone | $         $ 85,300,000            
Percentage of royalty payable by the counter party         50.00%            
Term of arrangement         10 years            
Term of arrangement, after first commercial sale         2 years            
Number of days of prior written notice | D         180            
Progenics Purchase Agreement                      
Commitments and Contingencies                      
Amount of milestone payments payable | $             $ 5,000,000        
Percentage of royalty payable             3.50%        
Amount payable upon filing BLA with FDA | $             $ 500,000        
Amount payable upon FDA approval | $             500,000        
Annual maintenance fees | $             $ 150,000        
Progenics Purchase Agreement | Royalty Payable in Initial 10 Years                      
Commitments and Contingencies                      
Percentage of royalty payable             5.00%        
Lonza Agreement                      
Commitments and Contingencies                      
Number of contract manufacturers | item             2        
Annual license fee             $ 700,000 £ 0.6      
Royalty on net sales (as a percent)             2.00% 2.00%      
Accounts Payable | Samsung BioLogics Co., Ltd. ("Samsung")                      
Commitments and Contingencies                      
Past due balance | $           $ 32,000,000.0 $ 33,700,000